Exelixis (EXEL) Debt to Equity Ratio
Current and historical debt to equity ratio values for Exelixis (EXEL) over the last 10 years.
|Medical||Medical - Biomedical and Genetics||$7.301B||$0.452B|
|Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.|